eylea beat inventori competit
eylea beat inventori offset higher rebat npdr approv highli like
us eylea revenu beat consensu
estim beat may driven inventori offset higher rebat
per manag previou statement provid guidanc eylea
onward view problemat confus sinc drug
still grow well worri investor assum competit concern
prompt manag drop us eylea guidanc submit sbla
dose interv wet target action date august
brolucizumab threat novarti remain acknowledg novarti
brolucizumab also dose everi week shown non-inferior eylea
data numer inferior furthermor hawk studi
harrier studi subject dose indic signific number
patient still requir frequent dose
panorama impact like take time eylea
non-prolif diabet retinopathi condit physician may
immedi treat upon diagnosi thu believ commerci upsid eylea
may take time materi phase panorama studi eylea
moder sever sever non-prolif diabet retinopathi npdr show
posit top-lin data wherein eylea-tr patient experienc two-step
greater improv baselin diabet retinopathi sever scale drss
week vs placebo
dupix ww miss pediatr indic key
world-wide net sale dupix miss consensu
estim attribut deduct expect
dupix acceler approv pediatr atop dermat indic around
make bulk opportun also expect off-label use
pediatr segment due sensit treat children without fda approv
initi phase studi younger pediatr sever atop dermat
patient month year old close monitor
maintain hold lower pt cemiplimab interest front-lin lung challeng
maintain hold rate lower pt base concern
lack eylea guidanc go forward dupix competit ahead expect
pediatr market uptick level competit eylea roch
dme novarti brolucizumab wet soon late target
base averag dcf price-to-earnings analys cemiplimab approv
cscc highli like octob continu monitor develop front-
line nsclc trial high bar success incumb therapi
biotech discov
invent manufactur commerci medicin
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
figur actual vs consensu cg estim
hold unchang target price may
regeneron actual vs estim except per actualconsensuscanaccordconsensuscanaccordeylea- eylea- sanofi collabor bayer collabor net product total sg oper net incom net incom ep fulli non- ep fulli estimatesactu vs full year estim except per share newoldtot net product us sanofi collabor bayer collabor sg net incom net incom ep ep canaccord guidanceoldchang non- billionyesnon- billionyescap millionyescash tax non- pre-tax reimburs milliony figur upcom expect catalyst
hold unchang target price may
aug oct oct regulatori submiss npdr non-dm patientsregulatorysubmit cardiovascular risk reduct us eu treatment hyperlipidemia usregulatori sbla expand indic adolesc year age atop dermatitisfda decis uncontrol persist asthmafda decis bla advanc regulatori submiss pre-fil syring formulationdata ph studi osteoarthritisfda decis dose interv wet amddata ph year age atop dermatitisdata ph polypsregulatori ex-u regulatori agenc decis applic adult atop dermat regulatori aug decis sbla use apheresi figur valuat dcf
hold unchang target price may
regeneron dcf valuat free yoy depreci capit work capit firm rate termin outstand valu per equiti risk-fre rate beta risk equiti risk-fre rate beta risk growth ratewacctermin growth rate regeneron
hold unchang target price may
hold unchang target price may
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- regeneron inc figur incom statement
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose
contact inform appear front page report
hold unchang target price may
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option sg collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand regeneron inc regeneron
